Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 701 - 750 of 1868 results
- Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin a.
- Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models.
- The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis.
- Scavenger receptor-a negatively regulates antitumor immunity.
- Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205.
- The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function.
- CD4+CD25+ T Regulatory Cells Dominate Multiple Immune Evasion Mechanisms in Early but Not Late Phases of Tumor Development in a B Cell Lymphoma Model.
- Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients.
- Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer-a phase I clinical trial.
- A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
- N-Acetyl-d-glucosamine substituted calix[4]arenes as stimulators of NK cell-mediated antitumor immune response.
- Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
- Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
- Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.
- Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines.
- Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
- Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus Monkeys.
- Anti-tumor activity of cationic liposomes conjugated adenovirus containing CCL19 gene.
- Mice with enhanced macrophage Angiotensin-converting enzyme are resistant to melanoma.
- Immunohistochemical Evaluation of H-R3 a Novel Humanized Monoclonal Antibody That Neutralizes the EGF-receptor.
- 'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'.
- Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
- Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
- Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.
- Phase I Trial of BAY 50-4798, an Interleukin-2-Specific Agonist in Advanced Melanoma and Renal Cancer.
- In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas.
- Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.
- Systemic Administration of IL-23 Induces Potent Antitumor Immunity Primarily Mediated through Th1-Type Response in Association with the Endogenously Expressed IL-12.
- Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
- Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
- Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
- Fast-tracked CTL: Rapid induction of potent anti-tumor killer T cells in situ.
- Susceptibility of cancer cells to herpes simplex virus-dependent apoptosis.
- Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
- Intratumoral injection of IL-12 plasmid DNA - results of a phase I/IB clinical trial.
- Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
- Local Expression of SLC Deliveryed by Adeno-associated Virus Within the Tumor Bed Stimulates Strong Anti-liver Tumor Immunity.
- Monoclonal Antibodies to Six-Transmembrane Epithelial Antigen of the Prostate-1 Inhibit Intercellular Communication In vitro and Growth of Human Tumor Xenografts In vivo.
- The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.
- Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes.
- Peptide vaccines of the her-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
- Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow.
- Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
- Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
- Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
- Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.
- Pre-clinical Evaluation of a CEA DNA Prime/protein Boost Vaccination Strategy Against Colorectal Cancer.
- Enhancing antitumor immunity: combining IL-12 with TGFbeta1 antagonism.
- Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model.
- Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.